| Exceptional response to erdafitinib in FGFR2-mutated metastatic pancreatic ductal adenocarcinoma CF Ng, J Glaspy, VR Placencio-Hickok, S Thomassian, J Gong, A Osipov, ... Journal of the National Comprehensive Cancer Network 20 (10), 1076-1079, 2022 | 17 | 2022 |
| A comparison of clinicopathologic outcomes across neoadjuvant and adjuvant treatment modalities in resectable gastric cancer E Anderson, A LeVee, S Kim, K Atkins, M Guan, V Placencio-Hickok, ... JAMA Network Open 4 (12), e2138432-e2138432, 2021 | 15 | 2021 |
| Race, sex, age, and geographic disparities in pancreatic cancer incidence. N Moshayedi, AL Escobedo, S Thomassian, A Osipov, AE Hendifar Journal of Clinical Oncology 40 (4_suppl), 520-520, 2022 | 12 | 2022 |
| Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma J Gong, S Thomassian, S Kim, G Gresham, N Moshayedi, JY Ye, JC Yang, ... Scientific reports 12 (1), 15013, 2022 | 8 | 2022 |
| Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis VR Placencio-Hickok, M Lauzon, N Moshayedi, M Guan, S Kim, N Nissen, ... Pancreatology 22 (1), 92-97, 2022 | 7 | 2022 |
| Plasma metabolomics predicts chemotherapy response in advanced pancreatic cancer H Muranaka, A Hendifar, A Osipov, N Moshayedi, V Placencio-Hickok, ... Cancers 15 (11), 3020, 2023 | 6 | 2023 |
| Gut microbiome and pancreatic cancer cachexia: an evolving relationship A Hendifar, R Akinsola, H Muranaka, A Osipov, S Thomassian, ... World Journal of Gastrointestinal Oncology 14 (7), 1218, 2022 | 5 | 2022 |
| Enhancing the design and evaluation of care delivery for patients on oral anticancer agents B Muluneh Journal of the National Comprehensive Cancer Network 20 (10), 1185-1187, 2022 | 3 | 2022 |
| Fecal microbiome composition in pancreatic cancer cachexia and response to nutrition support. N Moshayedi, J Yang, V Lagishetty, J Jacobs, V Placencio-Hickok, ... Journal of Clinical Oncology 39 (15_suppl), 4129-4129, 2021 | 2 | 2021 |
| Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma, primary tumors, and sites of metastasis. V Placencio-Hickok, M Lauzon, N Moshayedi, M Guan, S Kim, SJ Pandol, ... Journal of Clinical Oncology 39 (15_suppl), e16231-e16231, 2021 | 2 | 2021 |
| Correlation of MEN1 and DAXX mutational status with response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors PC Lee, EM Blais, J Gong, A Osipov, N Moshayedi, S Thomassian, C Ng, ... Endocrine Abstracts 89, 2023 | 1 | 2023 |
| Genomic correlates of response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors. P Lee, EM Blais, J Gong, A Osipov, N Moshayedi, S Thomassian, C Ng, ... Journal of Clinical Oncology 40 (16_suppl), 4124-4124, 2022 | 1 | 2022 |
| Plasma metabolomics to predict chemotherapy (CTX) response in advanced pancreatic cancer (PC) patients (pts) on enteral feeding for cachexia. H Muranaka, N Moshayedi, AE Hendifar, A Osipov, V Placencio-Hickok, ... Journal of Clinical Oncology 40 (4_suppl), 600-600, 2022 | 1 | 2022 |
| Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study J Gong, M Guan, H Kim, N Moshayedi, S Mehta, G Cook-Wiens, ... Oncotarget 13, 1202, 2022 | 1 | 2022 |
| Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma J Gong, S Thomassian, S Kim, G Gresham, N Moshayedi, YY Jason, ... Scientific reports 12, 2022 | 1 | 2022 |
| Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support N Bhowmick, R Akinsola, S Billet, H Muranaka, JP Jacobs, A Abbas, ... Preprints, 2024 | | 2024 |
| Mo1144 DECREASED EXPRESSION OF HISTONE DEACETYLASE 4 (HDAC4) AND YES-ASSOCIATED PROTEIN 1 (YAP) IN IMMUNOSUPPRESSIVE MYELOID CELLS AND FIBROBLASTS IN THE TME OF PANCREATIC … OH Elmadbouh, J Davelaar, A Lim, AA Abbas, A Minasyan, W Zhou, Y Ou, ... Gastroenterology 164 (6), S-773, 2023 | | 2023 |
| Suppression of phosphorylated focal adhesion kinase+ (pFAK+) fibroblasts and CXC chemokine receptor type 4 (CXCR4) expressing granulocytes is associated with exceptional … J Davelaar, AA Abbas, A Minasyan, OH Elmadbouh, N Moshayedi, ... Cancer Research 83 (7_Supplement), 5854-5854, 2023 | | 2023 |
| Keratin 17 excludes CD8-positive T cells and recruits CD163-positive macrophages in pancreatic ductal adenocarcinoma. L Oblein, M Horowitz, M Hasan, S Babu, M Torrente-Goncalves, L Roa, ... CANCER RESEARCH 82 (22), 159-160, 2022 | | 2022 |
| Abstract C071: Keratin 17 excludes CD8-positive T cells and recruits CD163-positive macrophages in pancreatic ductal adenocarcinoma L Oblein, M Horowitz, M Hasan, S Babu, M Torrente-Goncalves, L Roa, ... Cancer Research 82 (22_Supplement), C071-C071, 2022 | | 2022 |
